Neutrophil-To-Lymphocyte Ratio Predicts Survival in European Patients With Hepatocellular Carcinoma Administered Sorafenib

Oncotarget - United States
doi 10.18632/oncotarget.21528
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

High Preoperative Neutrophil-Lymphocyte Ratio Predicts Poor Survival in Patients With Gastric Cancer

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2010English

Early Α-Fetoprotein Response Predicts Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

Journal of Hepatocellular Carcinoma
2015English

Pre-Treatment Neutrophil to Lymphocyte Ratio Predicts the Chemoradiotherapy Outcome and Survival in Patients With Oral Squamous Cell Carcinoma: A Retrospective Study

BMC Cancer
Cancer ResearchOncologyGenetics
2016English

Neutrophil/Lymphocyte Ratio Predicts Chemotherapy Outcomes in Patients With Advanced Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2011English

Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients With NSCLC

Materia Socio Medica
2016English

Prognostic Role of Neutrophil-To-Lymphocyte Ratio and Platelet-To-Lymphocyte Ratio in Patients With Bone Metastases

British Journal of Cancer
Cancer ResearchOncology
2018English

Sorafenib vs Nivolumab in Patients With Hepatocellular Carcinoma

Journal of Liver Research, Disorders & Therapy
2017English

Post-Progression Survival and Progression-Free Survival in Patients With Advanced Hepatocellular Carcinoma Treated by Sorafenib

Hepatology Research
HepatologyInfectious Diseases
2015English

Stratified Aspartate Aminotransferase-To-Platelet Ratio Index Accurately Predicts Survival in Hepatocellular Carcinoma Patients Undergoing Curative Liver Resection

Tumor Biology
MedicineCancer Research
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy